Seroepidemiological study of cytomegalovirus in haemodialysis Patients hospitalized in heamodialysis unit of Jahrom

Subject Areas : Virology

Vahid Hemayatkhah Jahromi ¹ , Karamatallah Dory ² , Hamid Reza Momeni ³ , Habiballah Jowhary ⁴ , Hossein kargar ⁵

1 - Department of Biology, Jahrom Branch, Islamic Azad University, Jahrom, Iran.
2 - Department of Microbiology, Jahrom Branch, Islamic Azad University, Jahrom, Iran.
3 - Department of Biology, Arak University, Arak, Iran.
4 - Department of Biology, Darab branch, Islamic Azad University, Darab, Iran.
5 - Islamic Azad University, Young Researcher Club, Jahrom, Iran

Received: 2013-06-21 Accepted : 2013-06-21 Published : 2011-08-01

Keywords: ELISA, IgM, IgG, Cytomegalovirus, Haemodialysis,

Abstract :

 Abstract Background and Objective: Cytomegalovirus leads to severe infection in individuals with immune deficiency and recipient of blood and its production. Infected blood reception,  and haemodialysis are some of the risk factor factors in primary infection of cytomegalovirus. In this case-control study, positive epidemiological of active and passive cytomegalovirus infection were investigated in haemodialysis patients and control group. Material and methods: Blood serums of 43 haemodialysis patients and 43 healthy controls, who were similar to the patients in terms of sex and age, were investigated for determination of specific anti IgG and IgM of cytomegalovirus. Results: Data revealed that 39 haemodialysis patient (69.90%) were positive for anti- IgG CVM and 8 haemodialysis (18.60%) were positive for anti-IgG CMV (active infection with cytomegalovirus) while active infection with cytomegalovirus in control group had significant difference with patient group (36.2%). Conclusion: Cytomegalovirus cause severe infection in haemodialysis patients, and the rate of infection is directly relatd totransfusion repetitions.

References:

1. Danziger J. Importance of low-grade albuminuria. Mayo Clin Proc. 2008; 83(7): 806-12.

2. Spellman CW. Aggressively managing type 2 diabetes mellitus, hyperlipidemia and bone loss. J Am Osteopath Assoc. 2008; 108(5): S20-7.

3. Weisbord SD, Mor MK, Resnick AL, Hartwig KC, Sonel AF, Fine MJ, Palevsky PM. Prevention, incidence and outcomes of contrast-induced acute kidney injury. Arch Intern Med. 2008; 168(12): 1325-32.

4. Dalekos GN, Zervou E, Elisaf M, et al. Antibodies to hepatitis E virus among several population in Greece: increased prevalence in an hemodialysis unit. Transfusion. 1998; 38(6): 589-595.

5. Tveit DJ, Hypolite IO, Poropatich RK, Hashieh P, Cruess D, Hawkes CA, Agodoa LY, Abbott KC. Hospitalizations for bacterial pneumonia after renal transplantation in the United States. J Nephrol. 2002; 15(3): 255-62.

6. Jayasekara D, Aweeka FT, Rodriguez R, Kalayjian RC, Humphreys MH, Gambertoglio JG. Antiviral therapy for HIV patients with renal insufficiency. J Acquir Immune Defic Syndr. 1999; 21(5): 384-95.

7. Neofytou E, Sourvinos G, Asmarianaki M, Spandidos DA, Makrigiannakis A. Prevalence of human herpes virus types 1-7 in the semen of men attending an infertility clinic and correlation with semen parameters. Fertil Steril. 2008; 91(6): 2487-2494.  

8.  Stagno S. Cytomegalovirus. In: Behrman RE, kliegman R, Jenson HB. Nelson textbook of pediatrics. 16th edition. New york: W.B Saunders; 2000: 1981-1983.

9. Asakiene E, Alekniene D, Supranaviciene L, Miglinas M. [Cytomegalovirus infection in kidney transplant recipients in Santariskes Clinics of Vilnius University Hospital]. Medicina Kaunas. 2007; 43 (1): 131-8.

10. Kamar N, Mengelle C, Esposito L, Guitard J, Mehrenberger M, Lavayssière L, Ribes D, Cointault O, Durand D, Izopet J, Rostaing L. Predictive factors for cytomegalovirus reactivation in cytomegalovirus-seropositive kidney-transplant patients. J Med Virol. 2008; 80(6): 1012-7.

11. Trakulic M, Jovanovich D, Ostojic G, et al. Cytomegalovirus infection with kidney diseases. Vojosanit pregl. 2000; 57(5): 63-67.

12. Hardiman AE, Botter KC, Roe CA, et al. Cytomegalovirus infection in dialysis patients. Clin nephrol. 1985; 23(1): 12-17.

13. Mandell G. Cytomegalovirus. In: Mandell, Douglas and Bennett. Principles and practice of infectious diseases. Fifth Edition. Churchill Livingstone. 2000: 1594-1595.

14. McCarthy JM, Karim MA and Keown PA. The cost impact of cytomegalovirus disease in renal transplant recipients. Transplantation. 1993; 55(6): 1277-1282.

15. Fitzgerald JT, Gallay B, Taranto SE, McVicar JP, Troppmann C and Chen X. Pretransplant recipient cytomegalovirus seropositivity and hemodialysis are associated with decreased renal allograft and patient survival. Transplantation. 2004; 77(9): 1405-1411.

16. Yaghoubi R, Behzadbehbahani A, Sabahi F, Roostaee MH, Alborzi AV Development of simple and rapid methods for isolation of polymorphonuclear leukocytes with superior purity from whole blood: Specific application for diagnosis of Cytomegalovirus infection in bone marrow transplant patients. Iranian South Medical Journal. 2003; 2(5): 123-118.[In Persian].

17.Aminzadeh Z, Yaqhmaee F, Gachkar L. The investigation of anticytomegalovirus antibodies in acute haemodialysis Patients in Labafinejad hospital. J blood. 1384; 3(2): 31-35. [In Persian].